Claims
- 1. A biologically active celery seed extract produced by a supercritical fluid extraction of an ethanolic extract of fresh celery seed.
- 2. The biologically active celery seed extract of claim 1, wherein said supercritical fluid extraction is performed at temperatures ranging from 30 to 40° C., between about 100 and 300 atmospheres, using carbon dioxide admixed with methanol.
- 3. The biologically active celery seed extract of claim 2, further comprising the fractionation step of silica column chromatography and elution in 1-20% diethyl ether in light petroleum.
- 4. The biologically active celery seed extract of claim 2, further comprising the fractionation step with LiALH reduction.
- 5. The biologically active celery seed extract of claim 4, further comprising a second reduction step.
- 6. The biologically active celery seed extract of claim 1; and
a pharmaceutically acceptable carrier.
- 7. A pharmaceutical formulation comprising a biologically active celery seed extract, and further comprising a second anti-inflammatory drug.
- 8. The pharmaceutical composition of claim 7, wherein said second anti-inflammatory drug is an NSAID.
- 9. The pharmaceutical composition of claim 8, wherein said NSAID is selected from the group consisting of fenoprofen calcium, nalfon, flurbiprofen, Ansaid, ibuprofen, ketoprofen, naproxen, anaprox, aflaxen, oxaprozin, diclofenac sodium, diclofenac potassium, cataflam, etodolac, indomethacin, ketorolac, nabumetone, sulindac, tolmetin sodium, fenamates, meclofenamate sodium, mefenamic acid, piroxicam, salicylic acid, diflunisal, aspirin, oxyphenbutazone, and phenylbutazone.
- 10. The pharmaceutical formulation of claim 7, wherein said extract is produced by a supercritical fluid extraction of an ethanolic extract of fresh celery seed.
- 11. The pharmaceutical formulation of claim 10, wherein said supercritical fluid extraction is performed at temperatures ranging from 30 to 40° C., between about 100 and 300 atmospheres, using carbon dioxide admixed with methanol.
- 12. A nutraceutical formulation comprising:
the biologically active celery seed extract of claim 1; and a food.
- 13. The nutraceutical formulation of claim 12, and further comprising a second anti-inflammatory drug.
- 14. A method for the treatment of acute or chronic inflammation, the method comprising:
administering an effective dose of a biologically active celery seed extract.
- 15. The method of claim 14, further comprising administering a second anti-inflammatory drug.
- 16. The method of claim 15, wherein said second anti-inflammatory drug is an NSAID.
- 17. The method of claim 16, wherein said NSAID is selected from the group consisting of fenoprofen calcium, nalfon, flurbiprofen, Ansaid, ibuprofen, ketoprofen, naproxen, anaprox, aflaxen, oxaprozin, diclofenac sodium, diclofenac potassium, cataflam, etodolac, indomethacin, ketorolac, nabumetone, sulindac, tolmetin sodium, fenamates, meclofenamate sodium, mefenamic acid, piroxicam, salicylic acid, diflunisal, aspirin, oxyphenbutazone, and phenylbutazone.
- 18. The method of claim 14, wherein said extract is produced by a supercritical fluid extraction of an ethanolic extract of fresh celery seed.
- 19. The method of claim 17, wherein said supercritical fluid extraction is performed at temperatures ranging from 30 to 40° C., between about 100 and 300 atmospheres, using carbon dioxide admixed with methanol.
- 20. A method of reducing gastric irritation, the method comprising:
administering an effective amount of a biologically active celery seed extract.
- 21. The method of claim 20, wherein said gastric irritation is caused by administration of an NSAID.
- 22. The method of claim 21, wherein said NSAID and said celery seed extract are co-administered.
- 23. The method of claim 20, wherein said extract is produced by a supercritical fluid extraction of an ethanolic extract of fresh celery seed.
- 24. The method of claim 23, wherein said supercritical fluid extraction is performed at temperatures ranging from 30 to 40° C., between about 100 and 300 atmospheres, using carbon dioxide admixed with methanol.
- 25. A biologically active celery seed extract having anti-inflammatory activity wherein a dose of 50 mg/kg of the extract exhibits the same or greater activity as 300 mg/kg of aspirin in the Whitehouse anti-inflammatory animal model.
- 26. The celery seed extract of claim 25 wherein the extract dose is 20 mg/kg.
- 27. The celery seed extract of claim 25 wherein the extract dose is 10 mg/kg.
- 28. The celery seed extract of claim 25 wherein the extract also has gastroprotective activity wherein a dose of 50 mg/kg of the extract reduces by at least about 50% the gastric lesions elicited by a probing dose of ibuprofen in the Rainsford and Whitehouse gastroprotection animal model.
- 29. The celery seed extract of claim 26 wherein the extract also has gastroprotective activity wherein a dose of 20 mg/kg of the extract reduces by at least about 70% the gastric lesions elicited by a probing dose of ibuprofen in the Rainsford and Whitehouse gastroprotection animal model.
- 30. The celery seed extract of claim 27 wherein the extract also has gastroprotective activity wherein a dose of 10 mg/kg of the extract reduces by at least about 50% the gastric lesions elicited by a probing dose of ibuprofen in the Rainsford and Whitehouse gastroprotection animal model.
- 31. A biologically active celery seed extract having gastroprotective activity wherein a dose of 50 mg/kg of the extract reduces by at least about 50% the gastric lesions elicited by a probing dose of ibuprofen in the Rainsford and Whitehouse gastroprotection animal model.
- 32. The celery seed extract of claim 31 wherein the extract dose is 20 mg/kg.
- 33. The celery seed extract of claim 31 wherein the extract dose is 10 mg/kg.
- 34. The celery seed extract of claim 32 wherein the gastric lesions are reduced by at least about 70%.
- 35. A method for prevention or treatment of acute or chronic inflammation comprising administering to a patient in need thereof, from about 20 mg/kg/day to about 50 mg/kg/day of the celery seed extract of claim 25.
- 36. A method for prevention or treatment of acute or chronic inflammation comprising administering to a patient in need thereof, from about 10 mg/kg/day to about 20 mg/kg/day of the celery seed extract of claim 26.
- 37. A method for prevention or treatment of acute or chronic inflammation comprising administering to a patient in need thereof, from about 1 mg/kg/day to about 10 mg/kg/day of the celery seed extract of claim 27.
- 38. A method for prevention or reduction of gastric irritation comprising administering to a patient in need thereof, from about 20 mg/kg/day to about 50 mg/kg/day of the celery seed extract of claim 31.
- 39. A method for prevention or reduction of gastric irritation comprising administering to a patient in need thereof, from about 10 mg/kg/day to about 20 mg/kg/day of the celery seed extract of claim 32.
- 40. A method for prevention or reduction of gastric irritation comprising administering to a patient in need thereof, from about 1 mg/kg/day to about 10 mg/kg/day of the celery seed extract of claim 33.
Priority Claims (2)
Number |
Date |
Country |
Kind |
PP7975 |
Dec 1998 |
AU |
|
PP6891 |
Nov 1998 |
AU |
|
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a Continuation of prior U.S. application Ser. No. 09/432,140 filed Nov. 2, 1999, which claims the benefit under 35 U.S.C. § 119(a) of prior foreign Australian application nos. PP7975 filed Dec. 30, 1998 and PP6891 filed Nov. 4, 1998, all of which are incorporated herein by reference.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09432140 |
Nov 1999 |
US |
Child |
10032956 |
Oct 2001 |
US |